Table 1 |
||||||
|
Demographic and disease characteristics of patients receiving the same treatment at vaccination and at 1 |
||||||
|
RA (n = 163) |
SpA (n = 139) |
|||||
|
|
||||||
|
Treatment group |
MTX monotherapy |
Anti-TNF monotherapy |
Anti-TNF + MTX |
Anti-TNF monotherapy |
Anti-TNF + MTX |
NSAID/analgesics |
|
|
||||||
|
Number of patients at vaccination |
85 |
79 |
89 |
83 |
83 |
86 |
|
|
||||||
|
Number (%) of patients remaining on original therapy at 1.5-year follow-up |
57 (67%) |
50 (63%) |
56 (63%) |
47 (47%) |
49 (59%) |
43 (50%) |
|
|
||||||
|
Age, mean (SD); years |
63.5 (11) |
59.9 (14) |
60.5 (9) |
50.3 (12) |
51.6 (11) |
52.8 (12) |
|
|
||||||
|
Female (%) |
77% |
90% |
75% |
38% |
57% |
49% |
|
|
||||||
|
Disease duration, mean (SD); years |
12.6 (10) |
19.8 (11) |
16.8 (11) |
16.8 (11) |
13.1 (10) |
13.6 (12) |
|
|
||||||
|
RF positive (%) |
81 |
86 |
84 |
- |
- |
- |
|
|
||||||
|
Anti-CCP positive (%) |
77 |
76 |
88 |
- |
- |
- |
|
|
||||||
|
HLA B27 positive (%) |
- |
- |
- |
53 |
33 |
63 |
|
|
||||||
|
Crnkic Kapetanovic et al. Arthritis Research & Therapy 2013 15:R1 doi:10.1186/ar4127 |
||||||
